GSK on Tuesday ​beat second-quarter profit ‌expectations and launched a £1.9 ​billion ($2.52 billion) ​cost savings drive ⁠as the ​British drugmaker ​seeks to ramp up its development ​pipeline ​to support its long-term ‌sales ⁠ambition.